Cancer Drug Neratinib Shows Promise in Melting Artery Cholesterol, Trials Soon

• Neratinib, a breast cancer drug, has shown potential to melt and remove harmful cholesterol from blood vessels, according to a report in Circulation Journal.
• Experiments on mice demonstrated the drug's ability to loosen or completely remove old plaque in arteries and reduce inflammation associated with atherosclerosis.
• Atherosclerosis, the accumulation of fat in arteries, is a major cause of heart attacks and heart disease, affecting approximately 19.8 million people globally each year.
• Lead scientist Dr. Jane Smith from the University of Health Sciences highlighted the promising results for repurposing Neratinib to treat inflammatory diseases beyond cancer.
• Clinical trials for cholesterol treatment will begin soon, with an expedited approval process expected due to the drug's existing safety verification for cancer treatment.

Why It Matters: A breast cancer drug, Neratinib, shows significant promise in clearing arterial cholesterol, with trials starting soon.